Promoter Methylation of the Retinoic Acid Receptor Beta2 (RARβ2) Is Associated with Increased Risk of Breast Cancer: A PRISMA Compliant Meta-Analysis

• Published in: PloS one Vol. 10; no. 10; p. e0140329
• Main Authors: Fang, Cheng, Jian, Zhi-Yuan, Shen, Xian-Feng, Wei, Xue-Mei, Yu, Guo-Zheng, Zeng, Xian-Tao
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 09.10.2015; Public Library of Science (PLoS)
• Subjects: Acids; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer; Cell receptors; Confidence intervals; Data processing; DNA Methylation; Genetic aspects; Genetic Predisposition to Disease - genetics; Health risks; Humans; Medical diagnosis; Meta-analysis; Methylation; Patients; Physiological aspects; Promoter Regions, Genetic - genetics; Receptors, Retinoic Acid - genetics; Retinoic acid; Risk factors; Studies; Systematic review; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0140329

Epigenetic studies demonstrate that an association may exist between methylation of the retinoic acid receptor beta2 (RARβ2) gene promoter and breast cancer onset risk, tumor stage, and histological grade, however the results of these studies are not consistent. Hence, we performed this meta-analysis to ascertain a more comprehensive and accurate association. Relevant studies were retrieved from the PubMed, Embase and Chinese National Knowledge Infrastructure databases up to February 28, 2015. After two independent reviewers screened the studies and extracted the necessary data, meta-analysis was performed using Review Manager 5.2 software. Nineteen eligible articles, including 20 studies, were included in our analysis. Compared to non-cancerous controls, the frequency of RARβ2 methylation was 7.27 times higher in patients with breast cancer (odds ratio (OR) = 7.27, 95% confidence interval (CI) = 3.01-17.52). Compared to late-stage RARβ2 methylated patients, the pooled OR of early-stage ones was 0.81 (OR = 0.81, 95% CI = 0.55-1.17). The OR of low-grade RARβ2 methylated patients was 0.96 (OR = 0.96, 95% CI = 0.74-1.25) compared to high-grade RARβ2 methylated patients. RARβ2 methylation is significantly increased in breast cancer samples when compared to non-cancerous controls. RARβ2 could serve as a potential epigenetic marker for breast cancer detection and management.